A federal appeals court has rejected Teva Pharmaceuticals USA Inc.'s bid to overturn a permanent injunction barring the generic-drug maker from launching a copy of Eli Lilly & Co.'s blockbuster osteoporosis drug Evista® before March 2014. A three-judge panel of the U.S. Court of Appeals for the Federal Circuit on Wednesday affirmed the lower court's September 2009 determination that four of Lilly's seven patents covering the oral administration of raloxifene hydrochloride to combat bone loss in postmenopausal women were valid and would be infringed by Teva's proposed drug. Eli Lilly is represented by Finnegan.